Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Methodist Hospital

8303 Dodge Street, Omaha, NE 68114-4199 - USA

Cancer care at Methodist Hospital includes clinical experts, state-of-the-art technology, active clinical trials, and specialized cancer clinics for lung and thoracic cancers, head and neck cancers, breast cancer, and gynecologic cancer.

Methodist offers a multidisciplinary approach to cancer treatment. Medical specialists in oncology and other areas collaborate to develop a unique, comprehensive treatment plan for each cancer patient. Experts such as cancer nutritionists; cancer behavioral health specialists; physical, occupational, and speech therapists; and social workers take a holistic approach to provide care for the mind, body, and spirit of each patient.

Website: Methodist Estabrook Cancer Center

Contact:
Kathryn Bartz, Program Manager Oncology Research
402-354-7939

Trials at this location:

HCRN LUN19-427

Chemotherapy and Atezolizumab for Patients with Extensive Stage Small Cell Lung Cancer (SCLC) with Untreated, Asymptomatic Brain Metastases (HCRN LUN19-427)

Status: Open to Accrual
Read More

HCRN BRE12-158

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.

Status: Closed to Accrual
Read More

HCRN GI14-198

Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients

Status: Closed to Accrual
Read More

HCRN GU17-289

A Phase II Randomized, Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma (HCRN GU17-289)

Status: Closed to Accrual
Read More

HCRN GU17-295

A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

Status: Closed to Accrual
Read More

HCRN LUN14-179

A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab (MK-3475) for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179

Status: Closed to Accrual
Read More